MedTrace Logo

Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm

NCT00871065 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-08-15

No results posted yet for this study

Summary

Rupture of a cerebral aneurysm is a serious medical condition that may result in permanent disability or even death just related to the aneurysm rupture itself. Patients who undergo successful surgical treatment of their aneurysm will rarely experience problems related to that specific aneurysm in the future. However, blood that is on the surface of the brain from the initial aneurysm rupture is very irritating to other blood vessels that it comes in contact with. When these blood vessels become irritated, they spasm and become narrower. This narrowing restricts blood flow through the vessel, and if severe can result in a stroke that is caused by inadequate blood flow through the vessel. Depending on location and severity, this condition of vessel spasm (cerebral vasospasm) may result in permanent disability or death. Treatment to prevent cerebral vasospasm decreases the risk of stroke. This research is trying to see if a medication that is FDA approved for the treatment of lung disease and sexual dysfunction can be used to prevent and/or treat cerebral vasospasm.

Conditions

  • Cerebral Vasospasm
  • Subarachnoid Hemorrhage

Interventions

DRUG

Sildenafil citrate

20 mg tablet orally every 8 hours until Day 14 post-hemorrhage

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • William E Thorell, MD · University of Nebraska

  • Guy A Music, MD · University of Nebraska

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-02-25
Completion
2009-02-25

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871065 on ClinicalTrials.gov